title: GSK's Hidden Growth Engines Beyond HIV And Oncology
source: SeekingAlpha
date: 2025-10-09
url: https://finnhub.io/api/news?id=ee4aebd4250ddb46bf7735456b5f1abe9d3ddd42dfabc80b324a2accb000cca8
GSK plcâs strong oncology growth, highlighted by Ojjaara sales and an upgraded 2025 outlook, earns a continued 'Buy' rating. Learn more about GSK stock here.
